A significant number of people with severe COVID-19 carried rare genetic variants in 13 genes known to be critical in the body’s defense against influenza virus, and more than 3.5% were completely missing a functioning gene.
While this study requires validation in a bigger patient group, the initial results suggest that one dose of ivermectin given to mild COVID-19 patients reduced viral load and the duration of symptoms such as cough and loss of smell and taste.
By Helen Albert, Senior Editor According to the World Health Organization, there are almost 250 vaccines in development to protect against COVID-19. Of these, 64 have reached the stage of being tested in clinical trials.
In a Phase 1 study among eight patients with advanced melanoma who received the NeoVax vaccine, after a median of four years, all of the patients remained alive and six patients had no signs of active disease.
Research suggests that a build-up of abnormal microRNAs could be behind the increased risk for Alzheimer’s disease seen in patients who have experienced traumatic brain injury.
About half of the patients who were very sick with COVID-19 were exhibiting a combination of high levels of both the dangerous antibodies and super-activated neutrophils, which are destructive, exploding white blood cells.
The results demonstrated that patients who were taking drugs to speed up the breakdown of fats in their lungs were recovering from lung infections caused by COVID-19 in a matter of days—with no mortality among these patients.
New research corroborates other studies that highlight potential associations between strong MAIT cell activation and severe COVID-19 outcomes and provide important information to help better understand the immune response to SARS-CoV-2 that could help develop new treatments.
The AZ vaccine was developed in collaboration with researchers at the University of Oxford and tested first in the UK and Brazil. Key advantages of AZD1222 are that it does not require ultra-cold storage and it may be the least expensive of the three lead vaccines in development.
The researchers showed that an intravenously injected radioiodinated spike protein of SARS-CoV-2 readily crossed the blood-brain barrier in male mice and was taken up by brain regions and entered the parenchymal brain space.
The new IDP consists of 30 different specificities targeting most major immune markers, conveniently grouped together in a single tube.
The promise of cell and gene therapies to solve some of our most challenging conditions, from rare diseases to cancers, has led this field to remain on the forefront of innovation. Advances in innovative technologies coupled with deeper scientific knowledge in cellular and molecular biology spurred a new era of growth in these advanced therapies.
Normally, confirming a pneumonia diagnosis requires growing bacterial samples from patients in a lab, which is time-consuming. The new test can identify 52 different pathogens, and can be done in around four hours, without needing to grow the bacteria.
Syntegra uses machine learning to create validated “synthetic data”—replicas of healthcare data that are designed to precisely duplicate its statistical properties, with patient privacy protected by removing all links to the original data.
Although the main purpose of the study was to assess safety, the researchers also found that the treatment significantly improved survival with 91% of the stem-cell treated patients surviving until 31 days after admission versus 42% of the control group.
The study is one of the first longitudinal analyses to show that people who were seropositive—that is, they had produced antibodies against the virus that causes COVID-19—become seronegative, which means there were no detectable antibodies after a certain point.
Autopsies have shown the presence of SARS-CoV-2 RNA and protein in anatomically distinct regions of the nasopharynx and brain, suggesting it enters the brain through the nose, and may inform diagnosis and measures to prevent infection.
Dubbed TriSilix, the chip performs a miniature version of polymerase chain reaction (PCR) testing on bodily fluids, feces, or environmental samples, according to the scientists at Imperial College London who developed the new technology.
DARPA identified five disease categories for which the devices should detect pathogens and biomarkers: respiratory illnesses, febrile illnesses, vector-borne illnesses, gastrointestinal illnesses, and sepsis.
The kit is designed for purification of circulating cfNDA and uses silica coated paramagnetic particles to purify cfDNA from less than 1 mL to greater than 10 mL of serum or plasma.
Known as CopyKAT (copy number karyotyping of aneuploid tumors), the tool serves as a computational method for detecting cancerous cells amidst large and complex data sets emerging from RNA-sequencing.
The team studied antibody and immune cell responses in more than 180 men and women who had recovered from COVID-19. They reported that these patients’ immune memory to the virus—across all immune cell types studied—was measurable for up to eight months after symptoms appeared.
A study carried out by NIH researchers suggests that severe COVID-19 can damage the brain. MRI scans showed damage to small blood vessels in the brain, but no signs of viral RNA were found in tissue samples, leading to the theory that the severe immune reaction seen in patients hospitalized with COVID-19 is likely to blame for this damage.
Researchers at the Sidney Kimmel Cancer-Jefferson Health say their investigation indicates that the circadian clock gene CRY1 promotes tumor progression by altering DNA repair and could represent a new therapeutic target for prostate cancer.
Guardant Reveal, is a plasma-only ctDNA test for detection of early-stage colorectal cancer, with additional cancer types to follow. The minimal residue disease test, which will have a turnaround time of seven days, had been in development since 2016 under the name LUNAR-1, and was launched for research use only in 2019.